<i>ERBB3</i> kinase domain mutations are rare in lung, breast and colon carcinomas

Abstract excerpt

Protein tyrosine kinases, which regulate cell signaling pathways mediating a number of processes in cell survival and growth, comprise a large fraction of the dominant oncogenes known to date. The EGFR family consisted of 4 receptor tyrosine kinases, EGFR (ERBB1/ HER1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4).1 Recent studies demonstrated that lung adenocarcinomas possessed EGFR gene mutations, which could...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Lung Cancer Treatments and Mutations
• Share to Monoclonal and Polyclonal Antibodies Research